The AASLD-IDSA guidelines recommend treatment for all patients with chronic HCV except those with a very short life expectancy that cannot be remediated by HCV therapy, liver transplantation, or other directed therapy.1 For Medicaid patients diagnosed with Hepatitis C, state imposed restrictions may prevent patients from receiving curative therapies despite their physicians determining that they are medically necessary.
In this program, Dr. Christian Ramers, Assistant Medical Director for Research and Special Populations at the Family Health Centers of San Diego, and Michael Ninburg, President of the World Hepatitis Alliance and Executive Director of the Hepatitis Education Project, discuss the evolving Medicaid Restriction environment (Fibrosis, Sobriety, and Prescriber) and what barriers still exist in allowing patients to receive treatment.
- AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed July 2018.
This module is intended for United States and Puerto Rico health care professionals only and was developed by AbbVie.